physalin F

SKU: orb1298689

Description

physalin F

Research Area

Cell Biology, Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 57423-71-9
• MW: 526.53
• Purity: 98.83% (May vary between batches)
• Formula: C₂₈H₃₀O₁₀
• SMILES: [H][C@@]12C(=O)[C@]34O[C@@]11[C@](O)(CC[C@@]5([H])[C@@]3([H])C[C@H]3O[C@]33CC=CC(=O)[C@]53C)C(=O)O[C@@]1(C)[C@@]1([H])C[C@]2(C)[C@@]([H])(CO4)C(=O)O1
• Target: Calcium Channel,Apoptosis
• Solubility: DMSO:60 mg/mL (113.95 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.9 mM)

Bioactivity

• In Vivo:
  Physalin F is a secosteroid with potent anti-inflammatory and immunomodulatory activities. A concentration-dependent inhibition of spontaneous proliferation of PBMC from HAM/TSP subjects was observed in the presence of physalin F, as evaluated by (3)H-thymidine uptake. The IC50 for physalin F was 0.97 0.11 μM. Flow cytometry analysis using Cytometric Bead Array (CBA) showed that physalin F (10 μM) significantly reduced the levels of IL-2, IL-6, IL-10, TNF-α and IFN-γ, but not IL-17A, in supernatants of PBMC cultures. Next, apoptosis induction was addressed by using flow cytometry to evaluate annexin V expression. Treatment with physalin F (10 μM) increased the apoptotic population of PBMC in HAM/TSP subjects. Transmission electron microscopy analysis of PBMC showed that physalin F induced ultrastructural changes, such as pyknotic nuclei, damaged mitochondria, enhanced autophagic vacuole formation, and the presence of myelin-like figures. In conclusion, physalin F induces apoptosis of PBMC, decreasing the spontaneous proliferation and cytokine production caused by HTLV-1 infection.
  Read more...
• In Vitro:
  METHODS: Three renal cancer cell lines (A498, ACHN, and UO-31) were treated with physalin F (0, 0.3, 1, 3, and 10 μg/mL, 24 h), and cell viability was determined by MTT assay. RESULTS Physalin F inhibited cell viability in human renal cancer cell lines A498, ACHN, and UO-31 in a concentration-dependent manner with IC50 values ​​of 1.40 μg/mL, 2.18 μg/mL, and 2.81 μg/mL, respectively. METHODS: A498 cells were incubated in the absence or presence of physalin F (10 μg/mL, 6, 12, 18, 24 hours) for the indicated time, and the cells were harvested and prepared for detection of (A) mitochondrial membrane potential using FACScan analysis; A498 cells were incubated in the presence of physalin F (10 μg/mL, 3, 6, 8, 12, 18, 24 hours) for the indicated time, and the cells were harvested and prepared for detection of pro-caspase-8, 9, caspase-3, PARP, and p53, p21 expression using Western blotting. RESULTS The expression of Bcl-2 protein family including Bcl-2 and Bcl-xL was decreased after treatment with physalin F, and physalin F induced apoptosis of A498 cells through a mitochondria-dependent pathway; physalin F induced apoptosis by inducing p53 and p21 proteins, followed by cleavage of caspase-8/-9/-3 and PARP.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

proliferation, physalin F, CaV2.3, CalciumChannel, Calcium Channel, Apoptosis, cytokine, PBMC, infection, inflammatory, immunomodulatory, inhibit, HTLV-1, Inhibitor

Compound Identifiers

PubChem CID

44577488